PDF(1570 KB)
CD20阳性不提示高白细胞计数急性B淋巴细胞白血病患儿预后不良
张陆阳, 陈晓娟, 王书春, 郭晔, 杨文钰, 陈玉梅, 张丽, 邹尧, 竺晓凡
中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (7) : 728-733.
PDF(1570 KB)
PDF(1570 KB)
CD20阳性不提示高白细胞计数急性B淋巴细胞白血病患儿预后不良
CD20 is not a poor prognostic factor for childhood B-lineage acute lymphoblastic leukemia with high white blood cell count
目的 探讨初诊骨髓白血病细胞CD20表达联合白细胞计数在儿童B系急性淋巴细胞白血病（B-ALL）预后评估中的价值。方法 回顾性分析2008年4月至2015年4月接受CCLG-ALL2008方案治疗的821例初诊B-ALL患儿的临床资料，并随访观察其生存情况。结果 821例患儿中，CD20阴性患儿547例（66.6%），CD20阳性患儿274例（33.4%）。694例白细胞 < 50×109/L（低白细胞计数）的患儿中，CD20阳性、CD20阴性患儿5年无事件生存（EFS）率分别为65.9%±3.2%、77.3%±2.0%（P=0.001），5年总生存（OS）率分别为78.3%±2.9%、87.5%±1.6%（P=0.005）；多因素分析示CD阳性是EFS率、OS率的独立危险因素（分别HR=1.634，P=0.001；HR=1.761，P=0.005）。127例白细胞≥50×109/L（高白细胞计数）的患儿中，CD20阳性、CD20阴性患儿5年EFS率分别为64.3%±7.7%、53.7%±5.5%（P=0.135），5年OS率分别为81.4%±6.4%、58.6%±5.6%（P=0.022）；多因素分析示CD20阳性是OS率的独立保护因素（HR=0.367，P=0.016）。结论 接受CCLG-ALL2008方案治疗的B-ALL患儿中，初诊低白细胞计数、CD20阳性表达者长期预后较差，而初诊高白细胞计数、CD20阳性表达者有较好的生存趋势。
Objective To study the significance of CD20 combined with white blood cell (WBC) count at diagnosis in the prognosis assessment in children with B-lineage acute lymphoblastic leukemia (ALL). Methods A retrospective analysis was performed on the medical data of 821 B-ALL children who were treated with CCLG-ALL2008 regimen from April 2008 to April 2015. Their survival status was followed up. Results Among the 821 children, 547 (66.6%) were negative, while 274 (33.4%) were positive for CD20 expression. Among 694 children with WBC < 50×109/L (lower WBC count), the 5-year EFS rates were 65.9%±3.2% and 77.3%±2.0% for CD20 positive and negative patients respectively (P=0.001); the 5-year OS rates were 78.3%±2.9% and 87.5%±1.6% for CD20 positive and negative patients respectively (P=0.005); CD20 positive expression was an independent risk factor for EFS (HR=1.634, P=0.001) and OS (HR=1.761, P=0.005). Among 127 children with WBC > 50×109/L (higher WBC count), the 5-year EFS rates was 64.3%±7.7% and 53.7%±5.5% for CD20 positive and negative patients respectively (P=0.135); the 5-year OS rate was 81.4%±6.4% and 58.6%±5.6% for CD20 positive and negative patients respectively (P=0.022); CD20 positive expression was an independent protective factor for OS (HR=0.367, P=0.016). Conclusions In children with B-ALL who are treated with CCLG-ALL2008 regimen, those with CD20 positive expression in lower WBC count at diagnosis have a poor prognosis; however, those with CD20 positive expression in higher WBC count at diagnosis have a better long-time survival.
急性淋巴细胞白血病 / CD20 / 白细胞计数 / 预后 / 儿童
Acute lymphoblastic leukemia / CD20 / White blood cell count / Prognosis / Child
[1] 衣晓丽, 刘晓明, 刘天峰, 等. CCLG-ALL2008方案治疗303例儿童ALL诱导期感染并发症分析[J]. 中国小儿血液与肿瘤杂志, 2017, 22(6):286-291.
[2] Chang H, Jiang A, Brandwein J. Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia[J]. Haematologica, 2010, 95(6):1040-1042.
[3] Isshiki Y, Ohwada C, Sakaida E, et al. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy[J]. Jpn J Clin Oncol, 2017, 47(11):1047-1054.
[4] Jeha S, Behm F, Pei D, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2006, 108(10):3302-3304.
[5] Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia[J]. Haematologica, 2010, 95(2):324-328.
[6] Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia[J]. Blood, 2009, 113(25):6330-6337.
[7] Yang S, Wang J, Zhao T, et al. CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia[J]. Oncotarget, 2017, 8(62):105397-105406.
[8] Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group study[J]. Blood, 1997, 89(11):3960-3966.
[9] Esteban RE, Christianne B, Alvaro A, et al. Prognostic effect of CD20 expression in adult B-cell acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(5):361-367.
[10] Mannelli F, Gianfaldoni G, Intermesoli T, et al. CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia:new insights from the molecular study of minimal residual disease[J]. Haematologica, 2012, 97(4):568-571.
[11] Solano-Genesta M, Tarín-Arzaga L, Velasco-Ruiz I, et al. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value[J]. Hematology, 2012, 17(2):66-70.
[12] 徐皓, 魏旭东, 尹青松, 等. CD20阳性成人急性B淋巴细胞白血病患者临床特点及预后相关分析[J]. 中华血液学杂志, 2015, 36(1):4-9.[13周进, 王婧, 刘辉, 等. B系急性淋巴细胞白血病中CD20表达及其对预后影响[J]. 中国实验血液学杂志, 2015, 23(3):619-622.
[14] Kim DY, Park HS, Choi EJ, et al. Immunophenotypic markers in adult acute lymphoblastic leukemia:the prognostic significance of CD20 and TdT expression[J]. Blood Res, 2015, 50(4):227-234.
[15] 兰洋, 陈晓娟, 邹尧, 等. CCLG-ALL2008方案治疗10岁以上儿童及青少年急性淋巴细胞白血病的疗效分析[J]. 中国当代儿科杂志, 2019, 21(5):405-410.
[16] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版. 北京:科学出版社, 2007:19-23.
[17] 陈波, 宪莹, 苏庸春, 等. CCLG-ALL 08方案治疗儿童急性淋巴细胞白血病毒副作用的临床研究[J]. 中国当代儿科杂志, 2013, 15(9):737-742.
[18] Kawabata KC, Ehata S, Komuro A, et al. TGF-β-induced apoptosis of B-cell lymphoma ramos cells through reduction of MS4A1/CD20[J]. Oncogene, 2013, 32(16):2096-2106.
[19] 聂述山, 赵文理, 季正华, 等. CD20阳性儿童前B急性淋巴细胞白血病临床特点与预后分析[J]. 中华血液学杂志, 2011, 32(4):275-277.
[20] Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment:setting the stage for anti-CD20 directed immunotherapy[J]. Blood, 2008, 112(10):3982-3988.
[21] Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient:evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group[J]. Cytometry B Clin Cytom, 2010, 78(3):147-153.
天津市科技计划（15ZXLCSY00010）。
